Intra-Cellular Therapies Inc. (NASDAQ:ITCI) major shareholder Alafi Capital Co Llc acquired 258,065 shares of the stock in a transaction that occurred on Monday, October 2nd. The shares were bought at an average cost of $15.50 per share, for a total transaction of $4,000,007.50. Following the completion of the transaction, the insider now directly owns 3,953,270 shares of the company’s stock, valued at approximately $61,275,685. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Intra-Cellular Therapies Inc. (NASDAQ ITCI) traded up 2.64% during mid-day trading on Tuesday, reaching $15.92. 1,013,501 shares of the company’s stock were exchanged. Intra-Cellular Therapies Inc. has a 52-week low of $7.85 and a 52-week high of $22.67. The company’s market cap is $691.31 million. The stock has a 50-day moving average price of $17.16 and a 200 day moving average price of $13.34.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.74) by $0.33. Intra-Cellular Therapies had a negative return on equity of 27.92% and a negative net margin of 32,834.94%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the company earned ($0.71) earnings per share. Intra-Cellular Therapies’s quarterly revenue was down 52.2% on a year-over-year basis. Equities analysts predict that Intra-Cellular Therapies Inc. will post ($2.36) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Intra-Cellular Therapies Inc. (ITCI) Major Shareholder Alafi Capital Co Llc Buys 258,065 Shares” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/03/intra-cellular-therapies-inc-itci-major-shareholder-alafi-capital-co-llc-buys-258065-shares.html.

ITCI has been the subject of a number of research analyst reports. BidaskClub downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Cantor Fitzgerald reissued a “buy” rating on shares of Intra-Cellular Therapies in a research note on Wednesday, August 9th. Piper Jaffray Companies set a $10.00 price target on shares of Intra-Cellular Therapies and gave the company a “hold” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, August 15th. Finally, Leerink Swann reaffirmed a “market perform” rating and issued a $12.00 price target on shares of Intra-Cellular Therapies in a research note on Tuesday, August 15th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.38.

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth approximately $103,000. Bank of America Corp DE raised its holdings in shares of Intra-Cellular Therapies by 53.4% in the first quarter. Bank of America Corp DE now owns 9,660 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 3,363 shares during the last quarter. Fred Alger Management Inc. acquired a new stake in shares of Intra-Cellular Therapies in the second quarter valued at approximately $161,000. Voya Investment Management LLC raised its holdings in shares of Intra-Cellular Therapies by 16.0% in the second quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 2,338 shares during the last quarter. Finally, Citigroup Inc. raised its holdings in shares of Intra-Cellular Therapies by 32.8% in the second quarter. Citigroup Inc. now owns 17,395 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 4,295 shares during the last quarter. 71.79% of the stock is owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Company Profile

ITI Inc is a United States-based company. The Company is a subsidiary of Intra-Cellular Therapies Inc

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.